APA

Mackler N. J., Pienta K. J., Dunn R. L., Cooney K. A., Redman B. G., Olson K. B., Fardig J. E. & Smith D. C. (20070925). Phase II evaluation of oral estramustine, oral etoposide, and intravenous paclitaxel in patients with hormone-sensitive prostate adenocarcinoma. : Clinical genitourinary cancer.

Chicago

Mackler Niklas J, Pienta Kenneth J, Dunn Rodney L, Cooney Kathleen A, Redman Bruce G, Olson Karin B, Fardig Judith E and Smith David C. 20070925. Phase II evaluation of oral estramustine, oral etoposide, and intravenous paclitaxel in patients with hormone-sensitive prostate adenocarcinoma. : Clinical genitourinary cancer.

Harvard

Mackler N. J., Pienta K. J., Dunn R. L., Cooney K. A., Redman B. G., Olson K. B., Fardig J. E. and Smith D. C. (20070925). Phase II evaluation of oral estramustine, oral etoposide, and intravenous paclitaxel in patients with hormone-sensitive prostate adenocarcinoma. : Clinical genitourinary cancer.

MLA

Mackler Niklas J, Pienta Kenneth J, Dunn Rodney L, Cooney Kathleen A, Redman Bruce G, Olson Karin B, Fardig Judith E and Smith David C. Phase II evaluation of oral estramustine, oral etoposide, and intravenous paclitaxel in patients with hormone-sensitive prostate adenocarcinoma. : Clinical genitourinary cancer. 20070925.